From the Journals

Financial incentives affect the adoption of biosimilars


 

FROM ARTHRITIS & RHEUMATOLOGY

European governments incentivize use of biosimilars

Dr. Guro L. Goll

Dr. Guro L. Goll

Government and institutional incentives have increased the adoption of biosimilars in Europe, wrote Guro Lovik Goll, MD, and Tore Kristian Kvien, MD, of the department of rheumatology at Diakonhjemmet Hospital in Oslo, in an accompanying editorial. Norway and Denmark have annual national tender systems in which biosimilars and reference products compete. The price of infliximab biosimilar was 39% lower than the reference product in 2014 and 69% lower in 2015. “Competition has caused dramatically lower prices both for biosimilars and also for the originator drugs competing with them,” wrote the authors.

In 2015, the government of Denmark mandated that patients on infliximab be switched to a biosimilar, and patients in Norway also have been switched to biosimilars. The use of etanercept in Norway increased by 40% from 2016 to 2019, and the use of infliximab has increased by more than threefold since 2015. “In Norway, the consequence of competition, national tenders, and availability of biosimilars have led to better access to therapy for more people in need of biologic drugs, while at the same time showing a total cost reduction of biologics for use in rheumatology, gastroenterology, and dermatology,” wrote the authors.

Dr. Tore K. Kvien, department of rheumatology, Diakonhjemmet Hospital, Oslo

Dr. Tore K. Kvien

Health care costs $10,000 per capita in the United States, compared with $5,300 for other wealthy countries in the Organization for Economic Cooperation and Development. Low life expectancy and high infant mortality in the U.S. indicate that high costs are not associated with better outcomes. “As Americans seem to lose out on the cost-cutting potential of biosimilars, this missed opportunity is set to get even more expensive,” the authors concluded.

The U.S. Department of Veterans Affairs, the National Institutes of Health, and the American Diabetes Association contributed funding for the study. Dr. Baker reported receiving consulting fees from Bristol-Myers Squibb and Gilead, and another author reported receiving research support paid to his institution by Pfizer and UCB, as well as receiving consulting fees from nine pharmaceutical companies. Dr. Goll and Dr. Kvien both reported receiving fees for speaking and/or consulting from numerous pharmaceutical companies, including Pfizer.

SOURCES: Baker JF et al. Arthritis Rheumatol. 2020 Apr 6. doi: 10.1002/art.41277.

Pages

Recommended Reading

Nearly 25% of U.S. adults take an obesogenic prescription drug
Journal of Clinical Outcomes Management
Ideal management of RA in pregnancy improves outcomes
Journal of Clinical Outcomes Management
Value analysis of JAK inhibitors for RA hampered by limited data
Journal of Clinical Outcomes Management
Comparison shows tighter treat-to-target approach provides better outcomes in RA
Journal of Clinical Outcomes Management
Joint replacement: What’s new in 2020
Journal of Clinical Outcomes Management
New guideline offers recommendations for reproductive health in patients with rheumatic diseases
Journal of Clinical Outcomes Management
Glucocorticoid use linked to mortality in RA with diabetes
Journal of Clinical Outcomes Management
Stronger links forged between RA and asthma, COPD
Journal of Clinical Outcomes Management
Treatment for RA, SpA may not affect COVID-19 severity
Journal of Clinical Outcomes Management
‘We’re in great distress here,’ infusion center CMO says
Journal of Clinical Outcomes Management